FindTrial
Sign In

Fluciclovine F18

DRUG14 trials

Sponsors

Bital Savir-Baruch, Jonsson Comprehensive Cancer Center, University of Utah, Emory University, M.D. Anderson Cancer Center

Conditions

Anatomic Stage IV Breast Cancer AJCC v8Biochemically Recurrent Prostate CarcinomaCervical CancerEndometrial CancerGlioblastomaGlioblastoma Multiforme of BrainGlioblastoma, IDH-WildtypeInvasive Breast Lobular Carcinoma

Early Phase 1

Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease
CompletedNCT03868020
M.D. Anderson Cancer CenterMetastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma in Cervical Lymph Node
Start: 2019-04-24End: 2024-03-22Updated: 2024-03-28
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
RecruitingNCT06613841
Abramson Cancer Center at Penn MedicineGlioblastoma, Glioblastoma Multiforme of Brain, Recurrent Glioblastoma
Start: 2025-05-01End: 2026-12-31Target: 15Updated: 2025-11-28

Phase 1

Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer
CompletedNCT04750473
Emory UniversityAnatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma, Metastatic Breast Lobular Carcinoma +1
Start: 2021-07-16End: 2024-03-21Updated: 2025-01-17

Phase 2

Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery
CompletedNCT03515577
Jonsson Comprehensive Cancer CenterRecurrent Prostate Carcinoma
Start: 2019-04-12End: 2019-04-25Updated: 2020-10-14
Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone
CompletedNCT03707184
University of UtahMetastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
Start: 2018-10-02End: 2022-02-03Updated: 2024-11-29
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Active, not recruitingNCT03762759
Emory UniversityProstate Adenocarcinoma
Start: 2019-05-10End: 2025-12-31Updated: 2024-05-17
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
RecruitingNCT05053152
NRG OncologyOligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma +2
Start: 2022-04-20End: 2029-02-01Target: 194Updated: 2026-01-14
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
RecruitingNCT06064097
National Cancer Institute (NCI)Stage III Nasopharyngeal Carcinoma AJCC v8, Stage II Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
Start: 2024-06-25End: 2026-12-31Target: 50Updated: 2026-04-03
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
RecruitingNCT06319027
ECOG-ACRIN Cancer Research GroupGlioblastoma, IDH-Wildtype
Start: 2024-04-11End: 2027-05-31Target: 100Updated: 2026-04-03

Phase 3

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
RecruitingNCT04423211
ECOG-ACRIN Cancer Research GroupBiochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma +1
Start: 2020-10-08End: 2032-12-31Target: 804Updated: 2026-04-03

Phase 4

Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.
NCT03349463
Bital Savir-BaruchCervical Cancer, Endometrial Cancer, Ovarian Epithelial Cancer
Start: 2018-11-14End: 2020-12-31Target: 30Updated: 2020-02-28
An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer
TerminatedNCT04134208
M.D. Anderson Cancer CenterMetastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Start: 2019-09-19End: 2022-06-28Updated: 2025-01-16

Unknown Phase

F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery
CompletedNCT03926507
M.D. Anderson Cancer CenterGlioblastoma
Start: 2019-04-30End: 2023-09-18Updated: 2024-10-09
18F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain
TerminatedNCT04462419
Mayo ClinicMetastatic Intracranial Malignant Neoplasm, Recurrent Intracranial Neoplasm
Start: 2020-08-18End: 2024-11-13Updated: 2025-09-10

Related Papers

Initial report of a randomized trial of post-prostatectomy prostate cancer radiotherapy using either fluciclovine ( <sup>18</sup> F) or PSMA ( <sup>68</sup> Ga) PET/CT for target dose-escalation.
Journal of Clinical Oncology2025-02-101 citations
An Accelerated Spectroscopic MRI Metabolite Quantification Based on a Deep Learning Method for Radiation Therapy Planning in Brain Tumor Patients
Cancers2025-01-271 citations
Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma.
2024-07-085 citations
Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.
Journal of Clinical Oncology2023-06-011 citations
NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).
Journal of Clinical Oncology2023-02-203 citations
Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.
Journal of Clinical Oncology2023-02-20
A Discordant Pattern of Uptake on 68Ga-PSMA PET/CT Versus 18F-Fluciclovine PET/CT in Radiation-Induced Hepatitis
Clinical Nuclear Medicine2023-01-147 citations
A Tale of 3 Tracers
Clinical Nuclear Medicine2022-09-063 citations
Phase III study of local or systemic therapy INtensification DIrected by PET in prostate CAncer patients with post-prostaTEctomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.
Journal of Clinical Oncology2021-05-203 citations
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
2021-05-0718 citations
PET-directed local or systemic therapy intensification in prostate cancer patients with post-prostatectomy biochemical recurrence: A trial of the ECOG-ACRIN Cancer Research Group (EA8191).
Journal of Clinical Oncology2021-02-202 citations
Comparison of recurrence patterns after surgery and radiation therapy with 68Ga-PSMA-11 PET/CT in nonmetastatic castrate-sensitive prostate cancer patients: A single-center post-hoc retrospective analysis in 787 patients.
Journal of Clinical Oncology2020-05-20
Total-Body <sup>68</sup>Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines
Journal of Nuclear Medicine2019-09-2047 citations
Prospective head-to-head comparative phase 3 study between <sup>18</sup>F-fluciclovine and <sup>68</sup>Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.
Journal of Clinical Oncology2019-05-20
Prospective head-to-head comparison of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT for localization of prostate cancer biochemical recurrence after primary prostatectomy.
Journal of Clinical Oncology2019-03-0113 citations